Physician profile
Shari Rubin
NPI 1083869820
$370.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $96.40 · 2021: $46.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82.68 | 2019-2020 | |
| Abbvie INC. | $46.80 | 2021 | |
| Novo Nordisk INC | $46.43 | 2019-2020 | |
| Sanofi Pasteur INC. | $32.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $28.65 | 2019 | |
| Astellas Pharma US INC | $24.71 | 2019 | |
| Glaxosmithkline, LLC. | $20.70 | 2019 | |
| Btg International INC. | $18.03 | 2020 | |
| Dynavax Technologies Corporation | $16.14 | 2019 | |
| Pfizer INC. | $14.07 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.87 | 2019 | |
| Genentech USA, INC. | $13.48 | 2019 | |
| Gilead Sciences, INC. | $12.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.